Eslicarbazepine-d4

Eslicarbazepine-d4 (BIA 2-194-d4) is deuterium labeled Eslicarbazepine. Eslicarbazepine is an oral anticonvulsant indicated for the adjunctive treatment of partial seizures.

Product Specifications

Product Name Alternative

BIA 2-194-d4

UNSPSC

12352005

Target

Beta-secretase; Isotope-Labeled Compounds; Sodium Channel

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling; Others

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Smiles

O=C(N1C2=C(C([2H])=C(C([2H])=C2C[C@H](O)C3=CC=CC=C31)[2H])[2H])N

Molecular Formula

C15H10D4N2O2

Molecular Weight

258.31

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Finelli E, et al. Patch testing in a case of eslicarbazepine and carbamazepine induced cutaneous reaction. Eur Ann Allergy Clin Immunol. 2018 Sep;50 (5) :229-231.|[3]Sibhghatulla Shaikh, et al. Aptiom (Eslicarbazepine Acetate) as a Dual Inhibitor of β-Secretase and Voltage-Gated Sodium Channel: Advancement in Alzheimer's Disease-Epilepsy Linkage via an Enzoinformatics Study. CNS & Neurological Disorders Drug Targets Volume 13 , Issue 7 , 2014.